Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
Status:
Completed
Trial end date:
2018-12-18
Target enrollment:
Participant gender:
Summary
Specific aim: To establish the proof of principle that treatment of "high breast cancer risk"
women with recombinant human chorionic gonadotropin (r-hCG) will change their breast
epithelium's high risk genomic profile to one similar to that identified in women with a
history of early full first term pregnancy.